Primary Cutaneous Histoplasma capsulatum Infection in a Patient Treated With Fingolimod: A Case Report

Area of Science:

• Mycology
• Immunology
• Dermatology

Background:

• Fingolimod is an immunomodulatory medication prescribed for multiple sclerosis (MS).
• Histoplasma capsulatum is a fungus causing histoplasmosis, typically a pulmonary infection.
• Immunocompromised individuals may experience disseminated or atypical H. capsulatum infections.

Observation:

• A patient undergoing fingolimod treatment for MS developed a cutaneous lesion.
• The lesion was diagnosed as a primary cutaneous infection with Histoplasma capsulatum.
• This presentation is unusual, as H. capsulatum infections are typically pulmonary.

Findings:

• The case demonstrates a rare instance of cutaneous histoplasmosis in an immunocompromised patient.
• Fingolimod's immunosuppressive effects may predispose patients to opportunistic infections like H. capsulatum.
• Atypical presentations of H. capsulatum should be considered in immunocompromised patients.

Implications:

• Clinicians should be aware of potential opportunistic infections in patients treated with fingolimod.
• Early recognition and treatment of atypical fungal infections are crucial for patient outcomes.
• This case underscores the importance of considering fungal infections in the differential diagnosis of skin lesions in immunocompromised patients.